The clinical trials cited in the professional monographs for ALA and ALC were included in this review, with case reports, letters, and other reviews included only if the content contributed information unavailable in the cited clinical trials, such as additional adverse reactions
Opportunities Outside of Diabetes and Obesity Additional Indications for Exploration Additional Indications for Exploration As new companies look to enter the incretin mimetic space, and existing players seek to expand their portfolios, its increasingly important to look beyond diabetes and obesity
This can lead to elevated blood sugar levels and is linked to metabolic syndrome and type 2 diabetes
Scientific reports , 10 (1), 18091
Similarly, semaglutide was originally approved for diabetes under the brand name Ozempic in 2017, and then later approved for obesity (under the name Wegovy) in 2021